Degree of tumor hypoxia and its spatial distribution could impact the therapeutic choices and lead to development of improved treatment plans. This study uses a hypoxia binding T1 contrast agent GdDO3NI, to evaluate the dependence of hypoxia activated pro-drug TPZ (Tirapazamine) on baseline tumor oxygenation and its effect on the oxygenation of two non-small cell lung cancer lines ( NCI-H1975 and patient derived xenograft M112004). GdDO3NI was able to report the changes in hypoxia distribution in the tumor models in response to Tirapazamine therapy and correlation with therapeutic effect.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords